Evidence map›Paper›PMID 36562945›Full record

ReviewDermatology and therapy2023

Healthcare Disparities in Atopic Dermatitis in Latin America: A Narrative Review.

Jorge Sánchez, Iris-Selva Ale, Maria Valeria Angles, Guillermo Guidos Fogelbach, Angela Marie Jansen, Roberto Takaoka, Arturo Borzutzky

Open access · goldAbstract readReview
In one paragraph

Review in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Barriers to Accessing Pediatric Healthcare in Latin America: A Scoping Review.Journal of racial and ethnic health disparities · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 6 countries.

Jorge SánchezGroup of Clinical and Experimental Allergy, Hospital "Alma Mater de Antioquia" University of Antioquia, Cra. 27 n 37 B Sur 69 apto 510, Medellín, Colombia. jorgem.sanchez@udea.edu.co.ORCID http://orcid.org/0000-0001-6341-783X
Iris-Selva AleAllergy Unit & Department of Dermatology, University Hospital, Republic University of Uruguay, Montevideo, Uruguay.
Maria Valeria AnglesDermatology Department of Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.ORCID http://orcid.org/0000-0002-2149-4308
Guillermo Guidos FogelbachSchool of Medicine, ENMH, Instituto Politecnico Nacional, Mexico City, Mexico.ORCID http://orcid.org/0000-0003-1675-3894
Angela Marie JansenAmericas Health Foundation, Washington, DC, USA.ORCID http://orcid.org/0000-0003-2980-2421
Roberto TakaokaDivision of Dermatology, University of São Paulo Medical School Hospital, São Paulo, Brazil.ORCID https://orcid.org/0000-0003-0952-2641
Arturo BorzutzkyDepartment of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID http://orcid.org/0000-0002-7904-262X
Hospital Italiano de Buenos Aires · ARInstituto Politécnico Nacional · MXPontificia Universidad Católica de Chile · CLUniversidad de Antioquia · COUniversidad de Montevideo · UYUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAtopic dermatitis (AD) is a chronic, pruritic skin disease caused by a mixture of genetic, immunological, and environmental factors, characterized by periods of inflammation and remission. In Latin America (LA), the prevalence of AD ranges up to 25% in children and 1-3% in adults. The natural history of the disease for most patients is that AD goes into remission in adolescence and adult life. Only 10-30% of patients continue to have symptoms of the disease in adulthood. There are patients (3-4%) who have the onset of AD during adolescence or after adulthood. Those with limited access to healthcare services, such as diagnosis and treatment, have increased difficulties coping with AD. Healthcare disparities are a complex topic that include social, political, racial/ethnic, and geographical factors. Publications about healthcare disparities in AD in LA are scarce. As a result, recognizing and resolving healthcare inequalities is critical to improving the treatment and quality of life (QoL) of individuals with AD.

methodsA panel of Latin American experts in dermatology and allergies was provided with a series of relevant questions to address before a multiday conference. During this conference, the entire group discussed and edited each narrative through numerous drafts and rounds of discussion until they reached a consensus.

resultsThis paper examines the barriers to equal access to care and recommends realistic actions to overcome them. Inadequate disease knowledge, cultural and linguistic barriers, stigmatization, maldistribution of resources, absence of local clinical practice guidelines, arduous patient journey, and limited consultation time were identified as causes of health inequality.

conclusionsAmong the suggested solutions are enhanced education for healthcare professionals, patients, and the general public, a focus on underprivileged communities, telemedicine and telementoring, translators, multidisciplinary teams, and local living clinical practice guidelines.

Indexed as

Atopic dermatitisEczema in Latin AmericaHealthcare disparities in Latin AmericaLatin AmericaLatin America skin disease treatment optionsQuality of life for people with atopic dermatitis

Identifiers

PMID36562945
PMCPMC9786523
OpenAlexW4312161579

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.